Calton & Associates’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $823K | Sell |
6,839
-8,929
| -57% | -$1.03M | 0.12% | 166 |
|
|
2025
Q4 | $1.66M | Buy |
15,768
+1,144
| +8% | +$107K | 0.24% | 81 |
|
|
2025
Q3 | $1.23M | Buy |
14,624
+10,279
| +237% | +$847K | 0.18% | 101 |
|
|
2025
Q2 | $344K | Sell |
4,345
-109
| -2% | -$8.66K | 0.06% | 263 |
|
|
2025
Q1 | $400K | Buy |
+4,454
| New | +$416K | 0.09% | 201 |
|
|
2024
Q4 | – | Sell |
-4,490
| Closed | -$510K | – | 246 |
|
|
2024
Q3 | $510K | Buy |
4,490
+2,515
| +127% | +$299K | 0.19% | 115 |
|
|
2024
Q2 | $245K | Sell |
1,975
-754
| -28% | -$97.1K | 0.12% | 154 |
|
|
2024
Q1 | $360K | Sell |
2,729
-1,357
| -33% | -$167K | 0.18% | 125 |
|
|
2023
Q4 | $445K | Buy |
+4,086
| New | +$424K | 0.18% | 116 |
|
|
2023
Q3 | – | Sell |
-4,840
| Closed | -$558K | – | 202 |
|
|
2023
Q2 | $558K | Buy |
4,840
+1,139
| +31% | +$129K | 0.26% | 96 |
|
|
2023
Q1 | $394K | Sell |
3,701
-2,598
| -41% | -$280K | 0.18% | 124 |
|
|
2022
Q4 | $699K | Buy |
6,299
+2,120
| +51% | +$217K | 0.27% | 93 |
|
|
2022
Q3 | $359K | Sell |
4,179
-93
| -2% | -$8.3K | 0.21% | 120 |
|
|
2022
Q2 | $389K | Sell |
4,272
-1,506
| -26% | -$134K | 0.22% | 122 |
|
|
2022
Q1 | $474K | Sell |
5,778
-2,676
| -32% | -$211K | 0.14% | 173 |
|
|
2021
Q4 | $647K | Sell |
8,454
-1,223
| -13% | -$97.4K | 0.17% | 145 |
|
|
2021
Q3 | $726K | Sell |
9,677
-1,615
| -14% | -$123K | 0.16% | 155 |
|
|
2021
Q2 | $879K | Sell |
11,292
-942
| -8% | -$70.1K | 0.17% | 133 |
|
|
2021
Q1 | $900K | Sell |
12,234
-3,280
| -21% | -$242K | 0.18% | 116 |
|
|
2020
Q4 | $1.21M | Sell |
15,514
-1,279
| -8% | -$97.8K | 0.22% | 88 |
|
|
2020
Q3 | $1.33M | Buy |
16,793
+746
| +5% | +$58.4K | 0.27% | 68 |
|
|
2020
Q2 | $1.18M | Buy |
16,047
+919
| +6% | +$69.2K | 0.26% | 71 |
|
|
2020
Q1 | $1.11M | Sell |
15,128
-1,415
| -9% | -$111K | 0.28% | 68 |
|
|
2019
Q4 | $1.44M | Buy |
16,543
+1,086
| +7% | +$89.2K | 0.29% | 68 |
|
|
2019
Q3 | $1.24M | Buy |
15,457
+329
| +2% | +$26.4K | 0.28% | 69 |
|
|
2019
Q2 | $1.21M | Buy |
15,128
+424
| +3% | +$32.5K | 0.34% | 52 |
|
|
2019
Q1 | $1.17M | Sell |
14,704
-5,256
| -26% | -$393K | 0.36% | 54 |
|
|
2018
Q4 | $1.46M | Buy |
19,960
+2,993
| +18% | +$211K | 0.54% | 35 |
|
|
2018
Q3 | $1.15M | Sell |
16,967
-1,250
| -7% | -$79.6K | 0.34% | 55 |
|
|
2018
Q2 | $1.16M | Sell |
18,217
-3,853
| -17% | -$217K | 0.34% | 53 |
|
|
2018
Q1 | $1.15M | Buy |
22,070
+556
| +3% | +$30K | 0.33% | 58 |
|
|
2017
Q4 | $1.27M | Buy |
+21,514
| New | +$1.19M | 0.32% | 53 |
|
Other funds holding MRK
VCM
VPM
Calton & Associates's MRK Position: Q1 2026 in Review
Calton & Associates reduced its Merck (MRK) stake by 57% in Q1 2026, selling an estimated $1.03M and leaving 6,839 shares worth $823K. The position accounts for 0.12% of the portfolio, ranked #166.
Calton & Associates first reported a position in MRK in Q4 2017 and has held it in 32 quarters since. The position peaked at $1.66M in Q4 2025. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Calton & Associates held 6,839 shares of Merck worth $823K as of Q1 2026.
- Calton & Associates sold 8,929 Merck shares in Q1 2026, an estimated $1.03M.
- Merck made up 0.12% of Calton & Associates's portfolio in Q1 2026, its #166 holding.
- Calton & Associates first reported a position in Merck in Q4 2017 and has held it in 32 quarters since.
- Calton & Associates's Merck position peaked at $1.66M in Q4 2025.
- 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Calton & Associates's 13F filing for Q1 2026, filed 13 May 2026.